Last reviewed · How we verify
Lopinavir/r
Lopinavir/ritonavir is a protease inhibitor combination that blocks HIV protease, preventing viral polyprotein cleavage and maturation.
Lopinavir/ritonavir is a protease inhibitor combination that blocks HIV protease to prevent viral replication. Used for HIV-1 infection (treatment), COVID-19 (investigational use during pandemic).
At a glance
| Generic name | Lopinavir/r |
|---|---|
| Sponsor | Universidade Federal do Rio de Janeiro |
| Drug class | Protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Lopinavir inhibits HIV protease, the enzyme responsible for cleaving viral polyproteins into functional components necessary for viral replication. Ritonavir is a potent protease inhibitor included at low dose as a pharmacokinetic booster, inhibiting cytochrome P450 metabolism and dramatically increasing lopinavir plasma concentrations. Together, they prevent production of infectious viral particles and reduce viral load in HIV-infected patients.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
- COVID-19 (investigational use in some settings)
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Headache
- Lipid elevation (hypertriglyceridemia)
- Hepatotoxicity
- Pancreatitis
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission (PHASE1, PHASE2)
- Bone and Body Comp: A Sub Study of the SECOND-LINE Study (PHASE4)
- Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r (PHASE4)
- Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lopinavir/r CI brief — competitive landscape report
- Lopinavir/r updates RSS · CI watch RSS
- Universidade Federal do Rio de Janeiro portfolio CI